Efficacy observation of GDP regimen for treatment of relapsed and refractory non-Hodgkin lymphoma / 白血病·淋巴瘤

ABSTRACT

Objective To analyze the efficacy of GDP regimen for treatment of relapsed and refractory non-Hodgkin lymphoma (NHL). Methods The clinical data of 40 patients with relapsed and refractory NHL in the Third Hospital of Peking University from January 2009 to June 2014 were retrospectively analyzed. All the patients underwent GDP regimen (gemcitabine, dexamethasone, cisplatin). The clinical features, laboratory data and survival status were analyzed. Results The overall response rate (ORR) of 40 patients was 67.5 ％ (27/40) with 27.5 ％ (11/40) complete remission (CR) rate and 40.0 ％(16/40) partial remission rate. The 3-year overall survival (OS) rate was 86.5 ％ and the OS rate of 5-year was 28.8 ％. The ORR and 3-year OS rate in B-cell lymphoma and T-cell lymphoma were 69.6 ％ (16/23) vs. 52.9 ％ (9/17) (P=0.283), 90.9％vs. 80.7％(P=0.480). The CR rate in patients with gastrointestinal tract involvement was better than that in patients without gastrointestinal tract involvement (P= 0.049). Meanwhile, the patients with gastrointestinal tract involvement were superior in 3-year OS rate (89.3％vs. 76.2％, but the difference was not statistically significant (P = 0.237). The major side effect was hematological adverse reactions. The incidence of grade Ⅲ/Ⅳ neutropenia was 47.5 ％, the rate of Ⅲ/Ⅳthrombocytopenia was 40.0％and the rate ofⅢ/Ⅳanemia was 17.5％. Non-hematological adverse reactions included mild nausea and vomiting. Conclusions GDP regimen is effective and well tolerated in relapsed and refractory NHL with better efficacy for gastrointestinal tract involvement NHL patients.